Phaseline

Targets › ACVR2B

ACVR2B (Activin receptor type-2B): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 2; Metabolic and endocrine, Neurology; next expected readout Jan 2027.

Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH…. (UniProt, Q13705)

Open in Phaseline: the race on ACVR2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyBimagrumab (LY3985863)
Activin receptor type-2B antagonist
ACVR2BPhase 2ObesityJan 2027
Keros TherapeuticsKER-065
Activin type IIB receptor (ActR2B) ligand trap; inhibits myostatin and ActA signaling
ACVR2BPhase 2Duchenne Muscular DystrophyAug 2028

Conditions

Obesity (2) Duchenne Muscular Dystrophy (1)

Modalities

mixed (1), antibody (1)

Companies

Eli Lilly (1) Keros Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.